ADAM10 is upregulated in melanoma metastasis compared with primary melanoma

Sophia B Lee1, Anja Schramme, Kai Doberstein

  • 1Pharmazentrum frankfurt/ZAFES, Department of Pharmacology, University Hospital Goethe, University of Frankfurt, Frankfurt am Main, Germany.

Insights

ADAM10 (a disintegrin and metalloproteinase 10) and L1-CAM are elevated in melanoma metastasis, driving tumor growth and migration. Targeting these molecules may offer new melanoma treatment strategies.

Area of Science:

  • Oncology
  • Molecular Biology
  • Biochemistry

Background:

  • ADAM10 (a disintegrin and metalloproteinase 10) facilitates ectodomain shedding of substrates like L1-CAM and CD44.
  • L1-CAM and CD44 play roles in malignant melanoma development.

Purpose of the Study:

  • To characterize ADAM10 expression in melanoma cells.
  • To investigate the role of ADAM10 and L1-CAM in melanoma progression.

Main Methods:

  • Immunohistochemical analysis of tissue microarrays.
  • In vitro studies using small interfering RNA (siRNA) for ADAM10 downregulation.
  • Overexpression studies of ADAM10.
  • Analysis of L1-CAM knockdown and soluble L1-CAM effects.

Main Results:

  • ADAM10 expression is significantly elevated in melanoma metastasis compared to primary melanomas.
  • ADAM10 downregulation suppressed anchorage-independent growth and melanoma cell migration.
  • ADAM10 overexpression increased melanoma cell migration.
  • ADAM10 expression correlated with increased cell proliferation in metastatic melanoma.
  • ADAM10 mediates L1-CAM release; L1-CAM knockdown reduced migration and abrogated chemoresistance.

Conclusions:

  • ADAM10 and L1-CAM are crucial in melanoma progression.
  • Both ADAM10 and L1-CAM represent potential therapeutic targets for melanoma treatment.